文献速递胸部肿瘤放疗放疗物理与技术

心脏病、高血压和左前降支冠状动脉对数辐射剂量(CHyLL)模型预测肺癌放疗后主要不良心脏事件的外部验证

External validation of Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose (CHyLL) for predicting major adverse cardiac events after lung cancer radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-07-24

本研究在102例局部晚期非小细胞肺癌放疗患者中外部验证CHyLL模型预测主要不良心脏事件(MACE),CHyLL的C指数为0.73(95%CI 0.58-0.89),平均心脏剂量(MHD)的C指数为0.46(95%CI 0.30-0.62)。CHyLL低危组与高危组的MACE发生率在外部验证队列中log-rank p=0.108,在汇总队列(N=303)中log-rank p=0.01。结论认为CHyLL外部验证成功且优于MHD。

要点

  • CHyLL模型在外部验证队列中预测MACE的C指数为0.73(95%CI 0.58-0.89),优于MHD的0.46(95%CI 0.30-0.62)。
  • 外部验证队列中CHyLL低危组与高危组的MACE发生率差异log-rank p=0.108。
  • 汇总内部与外部验证队列(N=303)中低危组与高危组的MACE发生率差异log-rank p=0.01。

核心结论

  • CHyLL模型获得外部验证,在预测MACE方面优于MHD。
  • CHyLL有潜力识别可能从心脏肿瘤学优化中获益的高危患者,并基于心脏危险因素和可接受的MACE阈值估算个体化LADV15约束。

研究设计与样本

  • 研究纳入接受放疗的局部晚期非小细胞肺癌(LA-NSCLC)患者进行外部验证。
  • CHyLL评分计算公式为5.51×CHD + 1.28×HTN + 1.48×ln(LADV15 + 1) - 1.36×CHD×ln(LADV15 + 1)。
  • 采用Cox比例风险分析和Harrel一致性(C)指数评估CHyLL预测MACE的表现并与平均心脏剂量(MHD)比较。
  • 比较CHyLL低危组(<5)与高危组(≥5)的MACE和总生存(OS)。
  • 外部验证队列N=102,中位年龄71岁,55%为女性,73%(n=74)为临床III期疾病,34%(n=35)接受手术。

主要发现

  • 外部验证队列中CHyLL预测MACE的C指数为0.73(95%CI 0.58-0.89),MHD的C指数为0.46(95%CI 0.30-0.62)。
  • 按CHyLL分组,32例(31%)为低危,70例(69%)为高危。
  • 外部验证队列中低危组 vs 高危组MACE发生率:12个月0 vs 8%,24个月5 vs 16%,36个月5 vs 16%,48个月5 vs 19%(log-rank p=0.108)。
  • 汇总内部与外部验证队列(N=303)中低危组 vs 高危组MACE发生率:12个月1 vs 6%,24个月3 vs 12%,36个月6 vs 19%,48个月6 vs 21%(log-rank p=0.01)。

临床怎么用

  • 原文结论指出CHyLL有潜力识别可能从心脏肿瘤学优化中获益的高危患者,并基于心脏危险因素和可接受的MACE阈值估算个体化LADV15约束。

局限性

  • 外部验证队列中低危组与高危组的MACE发生率差异未达统计学显著(log-rank p=0.108)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Major adverse cardiac events(MACE) are prevalent in patients with locally advanced-non-small cell lung cancer(LA-NSCLC) following radiotherapy(RT). The CHyLL model, incorporating coronary heart disease(CHD),Hypertension(HTN),Logarithmic LADV15 was developed and internally-validated to predict MACE among LA-NSCLC patients. We sought to externally validate CHyLL to predict MACE in an independent LA-NSCLC cohort. PATIENTS AND METHODS: Patients with LA-NSCLC treated with RT were included. CHyLL score was calculated:5.51CHD + 1.28HTN + 1.48ln(LADV15 + 1)-1.36CHD*ln(LADV15 + 1). CHyLL performance in predicting MACE was assessed and compared to mean heart dose(MHD) using Cox-proportional hazard(PH) analyses and Harrel's concordance(C)-indices. MACE and overall survival(OS) among low-vs high-risk groups(CHyLL < 5 vs ≥ 5) were compared. RESULTS: In the external validation cohort(N = 102), the median age was 71 years and 55% were females. Most(n = 74,73%), had clinical Stage III disease and 35(34%) underwent surgery. CHyLL demonstrated good MACE prediction with C-index of 0.73(95% Confidence Interval(CI):0.58-0.89), while MHD did not (C-index = 0.46 (95% CI:0.30-0.62)). Per CHyLL, 32(31%) and 70(69%) patients were considered low-and high-risk for MACE, respectively. CHyLL consistently identified lower MACE rates in the low-vs high-risk group(log-rank p = 0.108):0 vs 8%(12 months),5 vs 16%(24 months),5 vs 16%(36 months),and 5 vs 19%(48 months) post-RT. In the pooled internal and external validation cohort(N = 303), MACE rates in low-vs high-risk groups were statistically significantly different(log-rank p = 0.01):1 vs 6%(12 months),3 vs 12%(24 months),6 vs 19%(36 months),and 6 vs 21%(48 months). CONCLUSIONS: CHyLL was externally validated and superior to MHD in predicting MACE. CHyLL has the potential to identify high-risk patients who may benefit from cardio-oncology optimization and to estimate personalized LADV15 constraints based on cardiac risk factors and acceptable MACE thresholds.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Tjong MC, Zhang SC, Gasho JO, et al. External validation of Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose (CHyLL) for predicting major adverse cardiac events after lung cancer radiotherapy. Clin Transl Radiat Oncol. 2023. PMID: 37545790. doi:10.1016/j.ctro.2023.100660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。